Oxford Biomedica (LON:OXB) Sets New 1-Year High – Still a Buy?

Oxford Biomedica plc (LON:OXB) shares hit a new 52-week high on Wednesday . The stock traded as high as GBX 791 and last traded at GBX 789, with a volume of 253045 shares trading hands. The stock had previously closed at GBX 739.

Analyst Upgrades and Downgrades

Several analysts recently commented on OXB shares. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a report on Friday, January 9th. Canaccord Genuity Group restated a “buy” rating and set a GBX 451 price objective on shares of Oxford Biomedica in a research report on Tuesday, October 7th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of GBX 606.40.

Oxford Biomedica Stock Up 1.3%

The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The company has a market cap of £904.08 million, a P/E ratio of -20.67 and a beta of 1.09. The stock has a 50-day moving average of GBX 630.56 and a 200 day moving average of GBX 556.63.

Insider Buying and Selling at Oxford Biomedica

In other news, insider Heather Preston acquired 6,175 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The shares were acquired at an average cost of GBX 593 per share, with a total value of £36,617.75. Company insiders own 34.83% of the company’s stock.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.